Status:
COMPLETED
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
Lead Sponsor:
AstraZeneca
Conditions:
Obesity
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
Eligibility Criteria
Inclusion
- Is obese with a body mass index (BMI) \>=30 kg/m\^2 to \<=50 kg/m\^2, and has been obese for at least one year before screening.
- Usually consumes at least three major meals (morning, midday, and evening) each day.
Exclusion
- Is currently enrolled in a formal weight-loss program.
- Has had liposuction within 1 year before screening or is planning to have liposuction during the study.
- Has received any investigational drug within 3 months before screening.
- Has previously participated in a study using pramlintide.
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00112021
Start Date
May 1 2005
End Date
November 1 2005
Last Update
April 10 2015
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Chula Vista, California, United States
2
Research Site
San Diego, California, United States
3
Research Site
Walnut Creek, California, United States
4
Research Site
Miami, Florida, United States